GENMARK DIAGNOSTICS, INC.

GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis

Retrieved on: 
Monday, February 22, 2021
Sarbecovirus, Zoonoses, Animal diseases, RP2, Severe acute respiratory syndrome coronavirus, Variants of SARS-CoV-2, Coronavirus disease, Health

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation.

Key Points: 
  • CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation.
  • As the COVID-19 pandemic continues to evolve, GenMark is routinely monitoring publicly available databases for new SARS-CoV-2 strains and variants and conducting bioinformatic analyses to determine if the mutations present in the viral genome would impact detection of these variants on the ePlex RP2 Panel.
  • GenMark will continue to update the list of variants detected by the ePlex RP2 Panel.
  • The EUA-authorized and CE-Marked ePlex RP2 Panel runs on GenMarks ePlex instrument, which is FDA cleared and CE-Marked for use with the companys ePlex RP Panel and Blood Culture Identification (BCID) Panels (Gram-positive, Gram-negative and Fungal pathogens).

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

Retrieved on: 
Tuesday, February 16, 2021

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.

Key Points: 
  • CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.
  • GenMarks management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m.
  • Interested parties can access the live and archived webcast at ir.genmarkdx.com
    GenMark Diagnostics(NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care.
  • GenMarks ePlex: The True Sample-to-Answer Solution is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels

Retrieved on: 
Tuesday, February 16, 2021
Medicine, Sepsis, Clinical medicine, Branches of biology, Bacterial diseases, Blood culture, Bloodstream infections, Fungemia, Antimicrobial resistance

The study, Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia, looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on ePlex BCID Panel results compared to standard of care.

Key Points: 
  • The study, Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia, looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on ePlex BCID Panel results compared to standard of care.
  • In an analysis of 158 bloodstream infection episodes, the ePlex Blood Culture Identification Panels were utilized to assess potential therapeutic interventions in a timelier manner compared to conventional microbiology.
  • With an overall sensitivity of 98%, the rapid result from the ePlex BCID Panels would have allowed the clinical team to modify treatment in 45% of patients.
  • Moreover, lack of an ePlex BCID result was considered a loss or a probable loss of opportunity for modification of therapy in 28% of patients.

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Retrieved on: 
Thursday, February 11, 2021
Diagnosis, Medical terminology

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close onThursday, February 25, 2021.

Key Points: 
  • CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close onThursday, February 25, 2021.
  • Management will hold a conference call to review the company's financial performance starting at4:30 p.m. ETon the same day.
  • The link to the webcast will be available on theGenMark Diagnostics, Inc.website at www.genmarkdx.com under the investor relations section and will be archived for future reference.
  • GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care.

GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020

Retrieved on: 
Monday, January 11, 2021
Economy of New York City, NASDAQ, Finance

CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020.

Key Points: 
  • CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020.
  • With multi-year contracts that include committed volumes, GenMark has created an enduring and recurring revenue stream that provides visibility to driving continued top line growth in 2021.
  • The company expects to issue full 2020 financial results and 2021 guidance in late February.
  • This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position.

GenMark Diagnostics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, December 28, 2020
Diagnosis, Medical terminology, Medical test

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.

Key Points: 
  • CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
  • GenMarks management is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference in a virtual setting on Tuesday, January 12th, 2021 at 5:20 p.m.
  • GenMarks management is also scheduled to present at the 23rd Annual Needham Growth Conference in a virtual setting on Thursday, January 14, 2021 at 5:00 p.m.
  • GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care.

GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

Retrieved on: 
Thursday, November 5, 2020

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum.

Key Points: 
  • CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum.
  • GenMarks management team is scheduled to present in a virtual setting on Thursday, November 19th, 2020 at 2:00 p.m.
  • GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care.
  • GenMarks ePlex:The True Sample-to-Answer Solution is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.

GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020

Retrieved on: 
Wednesday, October 14, 2020
Diagnosis, Medical terminology

CARLSBAD, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close onWednesday, October 28, 2020.

Key Points: 
  • CARLSBAD, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close onWednesday, October 28, 2020.
  • Management will hold a conference call to review the company's financial performance starting at1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
  • The link to the webcast will be available on theGenMark Diagnostics, Inc.website at www.genmarkdx.com under the investor relations section and will be archived for future reference.
  • GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care.